Gain Therapeutics, Inc.
GANX
Positions held
Your positionsGANX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $70.48M | Enterprise value | $58.01M | Trailing P/E | — | Forward P/E | -2.35 |
| PEG | — | Price / book | 6.19 | Beta | 0.19 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.7% | ROA | -95.5% | Debt / equity | 0.05 |
| Current ratio | 4.36 | Free cash flow | -$11.14M | Analyst recommendation | strong_buy | Mean target | $7.20 |
| 52w high | $4.34 | 52w low | $1.53 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.7M | -$5.6M | -$4.5M | -$5.3M | -$5.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.7M | -$5.4M | -$4.5M | -$4.8M | -$5.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.1M | $0.1M | — |
| Op margin | — | — | -40328.3% | -12688.1% | — |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Gain Therapeutics to Attend the 2026 Maxim Growth Summit
2026-09-17 · Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
2026-08-25 · Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-11 · Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
2026-07-16 · Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO
2026-07-16 · Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Price (daily)
Full chart · RSI · MACD · patterns